Jury Awards Innogenetics $7M in HCV Patent Case Against Abbott | GenomeWeb
NEW YORK (GenomeWeb News) - A federal jury late last week awarded Innogenetics $7 million in damages after unanimously finding Abbott Laboratores guilty of willfully infringing an Innogenetics patent covering a method of genotyping the hepatitis C virus.
 
The judge in the case can increase the award to up to three times the $7 million determined by the jury, Innogenetics said, because Abbott was found to have willfully infringed.
 
The jury decided the case in favor of Innogenetics earlier in the month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.